Rates of Torsades de Pointes Associated with Ciprofloxacin, Ofloxacin, Levofloxacin, Gatifloxacin, and Moxifloxacin
暂无分享,去创建一个
[1] J. Knoben,et al. An overview of the FDA publication Approved Drug Products with Therapeutic Equivalence Evaluations. , 1990, American journal of hospital pharmacy.
[2] L. Mandell,et al. Comparative Tolerability of the Newer Fluoroquinolone Antibacterials , 1999, Drug safety.
[3] P. Ball,et al. Quinolone-induced QT interval prolongation: a not-so-unexpected class effect. , 2000, The Journal of antimicrobial chemotherapy.
[4] F. Ponti,et al. QT-interval prolongation by non-cardiac drugs: lessons to be learned from recent experience , 2000, European Journal of Clinical Pharmacology.
[5] R. Owens. Risk Assessment for Antimicrobial Agent‐Induced QTc Interval Prolongation and Torsades de Pointes , 2001, Pharmacotherapy.
[6] P B Iannini,et al. Quinolone-induced QT interval prolongation: a not-so-unexpected class effect. , 2001, The Journal of antimicrobial chemotherapy.
[7] P. Iannini,et al. Evaluating the Risk of Cardiac Toxicity , 2001, Pharmacotherapy.
[8] S. Doddamani,et al. Risk of torsades de pointes with non-cardiac drugs , 2001, BMJ : British Medical Journal.
[9] P. Brown. Avoidance of ingestion of anti-inflammatory drugs in dyspepsia is confounding variable , 2001, BMJ : British Medical Journal.
[10] G. Tillotson,et al. New Milestones Achieved in Fluoroquinolone Safety , 2001, Pharmacotherapy.